Holen Sie sich die Stockscreener-App
3.74
1.58%
-0.06
Schlusskurs vom Vortag:
$3.80
Offen:
$3.72
24-Stunden-Volumen:
382
Relative Volume:
0.03
Marktkapitalisierung:
$67.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.63M
KGV:
-5.3875
EPS:
-0.6942
Netto-Cashflow:
$-12.18M
1W Leistung:
-2.09%
1M Leistung:
-2.86%
6M Leistung:
-2.35%
1J Leistung:
-18.70%
1-Tages-Spanne:
$3.70
$3.72
1-Wochen-Bereich:
$3.70
$3.84
52-Wochen-Spanne:
$2.74
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
Firmenname
Genenta Science Spa Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GNTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.70 | 69.50M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
368.76 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.01 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.35 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.28 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
290.00 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-29 | Fortgesetzt | ROTH MKM | Buy |
| 2022-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-13 | Eingeleitet | Maxim Group | Buy |
Genenta Science Spa Adr Aktie (GNTA) Neueste Nachrichten
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar - GlobeNewswire Inc.
Genenta secures $21.9 million for cancer drug trial By Investing.com - Investing.com South Africa
Genenta secures €20M in mandatory convertible bond deal - Investing.com India
Genenta secures €20M in mandatory convertible bond deal By Investing.com - Investing.com South Africa
Genenta secures $21.9 million for cancer drug trial - Investing.com India
Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research - TipRanks
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
Genenta Science Announces Shareholder Meeting - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Finanzdaten der Genenta Science Spa Adr-Aktie (GNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):